Literature DB >> 24972573

The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.

Yoshiyuki Yamamura1, Takahiro Tsuchikawa, Kengo Miyauchi, Shintaro Takeuchi, Masataka Wada, Toshihiko Kuwatani, Noriaki Kyogoku, Aki Kuroda, Takehiro Maki, Toshiaki Shichinohe, Satoshi Hirano.   

Abstract

BACKGROUND: It has recently been shown that certain chemotherapeutic agents can improve host immune responses. The present study aimed to demonstrate the mechanism by which chemotherapeutic agents modify the tumor microenvironment and induce tumor-specific immune responses.
METHODS: Three mouse cancer cell lines [CT26 mouse colon cancer cells, B16 melanoma cells and Lewis lung carcinoma (LLC)], 5 human carcinoma cell lines (human esophageal squamous cell carcinoma cell lines TE8 and HEC46 and the human pancreatic carcinoma cell lines PK-9, AsPC-1 and SUIT-2) and 5 chemotherapeutic agents [mitoxantrone (MIT), mitomycin C(MMC), 5-fluorouracil (5FU), camptothecin (CPT-11) and cisplatin (CDDP)] that are frequently used in a clinical setting for cancer treatment were utilized to investigate the surface expression level of calreticulin and HLA class I after exposure to chemotherapeutic agents.
RESULTS: Increased calreticulin (CRT) expression on the surface of mouse cell lines and, moreover, increased surface expression levels of both CRT and HLA class I in all human cell lines were observed in cells treated by the chemotherapeutic agents as compared with non-treated cells. The surface expression level of CRT was significantly correlated with the HLA class I expression level in all human cell lines.
CONCLUSIONS: In conclusion, chemotherapeutic drugs can improve the immunogenicity of cancer cells in a cell-specific manner through the mechanism of translocation of CRT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24972573     DOI: 10.1007/s10147-014-0719-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  22 in total

Review 1.  Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

Review 2.  Multimodal treatment strategies for locally advanced rectal cancer.

Authors:  Georg F Weber; Robert Rosenberg; Janet E Murphy; Christian Meyer zum Büschenfelde; Helmut Friess
Journal:  Expert Rev Anticancer Ther       Date:  2012-04       Impact factor: 4.512

3.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

4.  Distinct functions for the glycans of tapasin and heavy chains in the assembly of MHC class I molecules.

Authors:  Syed Monem Rizvi; Natasha Del Cid; Lonnie Lybarger; Malini Raghavan
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

5.  The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.

Authors:  Takahiro Tsuchikawa; Masaki Miyamoto; Yoshiyuki Yamamura; Toshiaki Shichinohe; Satoshi Hirano; Satoshi Kondo
Journal:  Ann Surg Oncol       Date:  2011-08-06       Impact factor: 5.344

Review 6.  MHC class I assembly: out and about.

Authors:  Malini Raghavan; Natasha Del Cid; Syed Monem Rizvi; Larry Robert Peters
Journal:  Trends Immunol       Date:  2008-09       Impact factor: 16.687

Review 7.  Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide.

Authors:  Sven Brode; Anne Cooke
Journal:  Crit Rev Immunol       Date:  2008       Impact factor: 2.214

8.  Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer.

Authors:  Takahiro Tsuchikawa; Satoshi Hirano; Eiichi Tanaka; Joe Matsumoto; Kentaro Kato; Toru Nakamura; Yuma Ebihara; Toshiaki Shichinohe
Journal:  Cancer Sci       Date:  2013-03-31       Impact factor: 6.716

9.  The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.

Authors:  Kousaku Mimura; Kensuke Shiraishi; Anja Mueller; Shinichiro Izawa; Ley-Fang Kua; Jimmy So; Wei-Peng Yong; Hideki Fujii; Barbara Seliger; Rolf Kiessling; Koji Kono
Journal:  J Immunol       Date:  2013-11-15       Impact factor: 5.422

10.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.

Authors:  K Hiraoka; M Miyamoto; Y Cho; M Suzuoki; T Oshikiri; Y Nakakubo; T Itoh; T Ohbuchi; S Kondo; H Katoh
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  11 in total

Review 1.  Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.

Authors:  Nicole S Klee; Cameron G McCarthy; Patricia Martinez-Quinones; R Clinton Webb
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-09-15

Review 2.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

3.  Induction of Immunogenic Cell Death of Esophageal Squamous Cell Carcinoma by 5-Fluorouracil and Cisplatin.

Authors:  Junya Nishimura; Sota Deguchi; Hiroaki Tanaka; Yoshihito Yamakoshi; Mami Yoshii; Tatsuro Tamura; Takahiro Toyokawa; Shigeru Lee; Kazuya Muguruma; Masaichi Ohira
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 4.  Immunogenic cell death in colon cancer prevention and therapy.

Authors:  Hang Ruan; Brian J Leibowitz; Lin Zhang; Jian Yu
Journal:  Mol Carcinog       Date:  2020-03-25       Impact factor: 4.784

Review 5.  Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.

Authors:  Ananthan Sadagopan; Theodoros Michelakos; Gabriella Boyiadzis; Cristina Ferrone; Soldano Ferrone
Journal:  JAMA Oncol       Date:  2022-03-01       Impact factor: 31.777

Review 6.  Combinatorial strategies for the induction of immunogenic cell death.

Authors:  Lucillia Bezu; Ligia C Gomes-de-Silva; Heleen Dewitte; Karine Breckpot; Jitka Fucikova; Radek Spisek; Lorenzo Galluzzi; Oliver Kepp; Guido Kroemer
Journal:  Front Immunol       Date:  2015-04-24       Impact factor: 7.561

Review 7.  Endoplasmic reticulum chaperones and oxidoreductases: critical regulators of tumor cell survival and immunorecognition.

Authors:  Tomás Gutiérrez; Thomas Simmen
Journal:  Front Oncol       Date:  2014-10-27       Impact factor: 6.244

Review 8.  Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer.

Authors:  Takahiro Tsuchikawa; Shintaro Takeuchi; Toru Nakamura; Toshiaki Shichinohe; Satoshi Hirano
Journal:  World J Gastrointest Oncol       Date:  2016-11-15

Review 9.  Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy.

Authors:  Jean-David Fumet; Emeric Limagne; Marion Thibaudin; Francois Ghiringhelli
Journal:  Cancers (Basel)       Date:  2020-09-16       Impact factor: 6.639

10.  Calreticulin is highly expressed in pancreatic cancer stem-like cells.

Authors:  Satoshi Matsukuma; Kiyoshi Yoshimura; Tomio Ueno; Atsunori Oga; Moeko Inoue; Yusaku Watanabe; Atsuo Kuramasu; Masanori Fuse; Ryouichi Tsunedomi; Satoshi Nagaoka; Hidetoshi Eguchi; Hiroto Matsui; Yoshitaro Shindo; Noriko Maeda; Yoshihiro Tokuhisa; Reo Kawano; Tomoko Furuya-Kondo; Hiroshi Itoh; Shigefumi Yoshino; Shoichi Hazama; Masaaki Oka; Hiroaki Nagano
Journal:  Cancer Sci       Date:  2016-11-04       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.